These data confirm the neuroprotective effect of 14-3-3ε via inhibiting neuronal apoptosis in vivo[24], [54], and provide first evidence that engineered TAT-14-3-3ε fusion protein could be developed as a novel therapeutic agent for the treatment of stroke and possibly other neurodegenerative diseases. Here, YWHAE is linked to stroke disorder.